Can Inflammatory and Nutritional Serum Markers Predict Chemotherapy Outcomes and Survival in Advanced Stage Nonsmall Cell Lung Cancer Patients?
Open Access
- 28 February 2019
- journal article
- research article
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-8
Abstract
Purpose. To determine the values of prognostic nutritional and inflammatory markers in chemotherapy outcomes and survival in the patients with advanced nonsmall cell lung cancer (NSCLC) and also in the secondary malnutrition and cachexia. Methods. Twenty-five patients with diagnosis of aNSCLC were registered for the prospective study. Malnutrition was determined by the Subjective Global Assessment (SGA) and performance status by criteria of the Eastern Cooperative Oncology Group (ECOG). Before treatment, serum levels of albumin, prealbumin, vitamin D, zinc (Zn), C-reactive protein (CRP), IL-6, IL-1 β, TNF-α, lipoprotein lipase (LPL), and the Glasgow Prognostic Score (GPS) were recorded. Patients were followed prospectively for treatment outcomes and survival. Results. Due to the deaths of 18 patients during the 4-month follow-up period, no adequate measurements of inflammatory and nutritional markers could be performed. However, seven patients completed the treatment period and evaluations of these markers could be performed during the three periods. Eighty-four percent of patients were male with a mean age of 63.3 ± 8.7 years. Evaluation of the malnutrition by SGA showed that 5 (20%) patients were well nourished (A), 12(48%) were moderately malnourished (B), and 8(32%) were severely malnourished (C). Low levels of serum albumin (α (≥24pg/ml), IL-1β (≥10pg/ml), and LPL (β, TNF-α, CRP, and LPL and also the reduced serum levels of albumin, prealbumin, Zn, vitamin D, and GPS, respectively. Similarly, Friedman analysis indicated that prealbumin significantly increased (p=0.007) in the follow-up period. But the serum levels of CRP (mean 37.3±22.3; Wilcoxon test P=0.368) in the seven patients were lower than those of the 18 patients that expired (mean 75.82±56.2). Conclusion. Malnutrition and cachexia negatively influence oncological outcomes in patients with NSCLC. These nutritional/inflammatory markers may be useful for selection of high risk and reduced survival in patients with aNSCLC undergoing adjuvant chemotherapy.Keywords
Funding Information
- Turkish Society of Geriatric Oncology
This publication has 41 references indexed in Scilit:
- A Consideration of Biomarkers to be Used for Evaluation of Inflammation in Human Nutritional StudiesBritish Journal of Nutrition, 2013
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapyCancer, 2011
- Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literatureNutrition Journal, 2010
- Zinc: role in immunity, oxidative stress and chronic inflammationCurrent Opinion in Clinical Nutrition and Metabolic Care, 2009
- Components of the anorexia–cachexia syndrome: gastrointestinal symptom correlates of cancer anorexiaSupportive Care in Cancer, 2009
- REPROGRAMMING OF THE IMMUNE SYSTEM DURING ZINC DEFICIENCYAnnual Review of Nutrition, 2004
- Inflammation and cancerNature, 2002
- Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancerEuropean Journal of Clinical Nutrition, 2002
- Reduced Plasma Lipoprotein Lipase Activity in Patients with Malignancy-Associated Weight LossHormone and Metabolic Research, 1986